Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy

This study has been completed.
Sponsor:
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT00566722
First received: December 1, 2007
Last updated: April 8, 2011
Last verified: April 2011
  Purpose

The objective of this study was to evaluate the safety and efficacy profile of Humira (adalimumab) in patients who had a sub-optimal response to prior systemic therapy. This open-label study was conducted in a patient population of moderate to severe chronic plaque psoriasis patients, which is an approved patient population for adalimumab.


Condition Intervention Phase
Psoriasis
Biological: adalimumab
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy

Resource links provided by NLM:


Further study details as provided by Abbott:

Primary Outcome Measures:
  • Number of Participants Who Achieved a Physician's Global Assessment (PGA) of Clear (0) or Minimal (1) at Week 16 [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
    The PGA is a 6-point scale used to measure the severity of a patient's disease. Plaque elevation, scaling, and erythema are rated from 0= clear (no plaque elevation; no scaling; erythema=hyperpigmentation, pigmented macules, diffuse faint pink or red coloration) to 5=very severe (plaque elevation=very marked; scaling=very coarse; erythema=very severe [extreme red coloration, dusky to deep red coloration]).


Secondary Outcome Measures:
  • Number of Participants Achieving a PGA of Clear (0) at Week 16 [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
  • Number of Participants Achieving at Least 1 Grade of Improvement in PGA at Week 16 Compared to Screening [ Time Frame: From Screening to Week 16 ] [ Designated as safety issue: No ]
  • Number of Participants Achieving 0 or 1 on Patient's Global Assessment at Weeks 2, 4, and 8 [ Time Frame: Weeks 2, 4, and 8 ] [ Designated as safety issue: No ]
    The Patient's Global Assessment of Psoriasis-Severity is a rating of how well their disease is controlled. 0=complete disease control; 1=good disease control; 2=limited disease control; 3=uncontrolled disease.

  • Dermatology Life Quality Index (DLQI) Total Score [ Time Frame: From Screening to Week 4 and Week 16 ] [ Designated as safety issue: No ]
    The DLQI has 10 items and 6 subscales: symptoms and feelings (Q 1 and 2), daily activities (Q 3 and 4), leisure (Q 5 and 6), work and school (Q 7), personal relationships (Q 8 and 9), and treatment (Q 10). Participants rate how much their skin problem affected their life in previous week. Responses are 0 (not at all) to 3=very much. DLQI=total of scores for all items; max=30; min=0.

  • Number of Participants Achieving DLQI Total Score of 0 at Week 4 and Week 16 [ Time Frame: Week 4 and Week 16 ] [ Designated as safety issue: No ]
    DLQI total score of 0 indicates psoriasis had no effect at all on participant's life.

  • Psoriasis-related Pruritus Assessment [ Time Frame: From Screening to Week 16 ] [ Designated as safety issue: No ]
    The Psoriasis-related Pruritus Assessment is a scale for evaluating pruritus-related to psoriasis over the previous week; values range from 0 (no itching) to 10 (severe itching). A decrease in score indicates an improvement in pruritus.

  • Visual Analog Scale (VAS) for Pain Involving Psoriatic Plaques and/or Psoriatic Arthritis [ Time Frame: From Screening to Week 16 ] [ Designated as safety issue: No ]
    The participant rates his/her pain during the previous week on a 100 mm VAS, from 0=no pain to 100=pain as bad as it could be. A decrease in score indicates improvement.

  • Percent Work Time Missed Due to Psoriasis [ Time Frame: From Screening to Week 16 ] [ Designated as safety issue: No ]
    Work and activity impairment due to psoriasis were evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP), a 6-item questionnaire that measures effect of psoriasis on number of hours worked and the number of hours missed from work. It also measures the effect on productivity and regular activities: 0=no effect on work/daily activities; 10=psoriasis prevented me from working/doing daily activities. Decreases in values on each part indicate improvement. At Screening, percent time missed in the previous week ranged from 0% to 40%.

  • Percent Overall Work Impairment Due to Psoriasis [ Time Frame: From Screening to Week 16 ] [ Designated as safety issue: No ]
    Percent overall work impairment was evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) (described above). At Screening, overall impairment ranged from 0% to 94%. A decrease in percent overall work impairment indicates improvement.

  • Percent Impairment While Working Due to Psoriasis [ Time Frame: From Screening to Week 16 ] [ Designated as safety issue: No ]
    Percent impairment while working was evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP), described above. At Screening, impairment while working ranged from 0% to 90%. A decrease in percent impairment indicates improvement.

  • Percent Activity Impairment Due to Psoriasis [ Time Frame: From Screening to Week 16 ] [ Designated as safety issue: No ]
    Percent impairment in regular activities was evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP), described above. At Screening, activity impairment due to psoriasis ranged from 0% to 90%.

  • Sleep Problems Index II [ Time Frame: From Screening to Week 16 ] [ Designated as safety issue: No ]
    Sleep Problems Index of the Sleep Scale from the Medical Outcomes Study reflects sleep disturbance, perceived sleep adequacy, daytime somnolence, and awakening short of breath or with headache. Participant rates each item from "none of the time" to "all of the time" for the previous 4 weeks. Scores are transformed to 0 to 100 scale; lower scores indicate less impairment. Decrease in score indicates improvement.


Enrollment: 152
Study Start Date: January 2008
Study Completion Date: April 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Open Label Biological: adalimumab
Participants received an 80 mg adalimumab loading dose by subcutaneous injection at Baseline (Week 0). From Week 1 to Week 15, participants received 40 mg adalimumab by subcutaneous injection every other week.
Other Names:
  • ABT-D2E7
  • adalimumab
  • Humira

Detailed Description:

This 16-week multicenter, open-label study was designed to evaluate the efficacy and safety of a loading dose of 80 mg adalimumab, followed by 40 mg adalimumab every other week in the treatment of psoriasis in patients with a sub-optimal response to etanercept, methotrexate (MTX), or Narrow band Ultraviolet − B (NB-UVB).

Approximately 150 participants were planned for 3 sub-studies: 80 participants with sub-optimal response to etanercept, 40 participants with sub-optimal response to MTX, and 30 participants with sub-optimal response to NB-UVB. Actual enrollment was 82 participants with sub-optimal response to etanercept, 41 participants with sub-optimal response to MTX, and 29 participants with sub-optimal response to NB-UVB.

Screening was performed at least 96 hours and no more than 31 days before the Baseline visit (Week 0). A participant who was eligible for the study based on sub-optimal response to one treatment (MTX, NB-UVB, or etanercept) was required to discontinue that treatment within a specified time before first dose of adalimumab (see descriptions of sub-study groups). In addition, if the participant was also receiving another qualifying treatment, he/she was required to have discontinued the other treatment at least 30 days before the Baseline visit (Week 0).

Adalimumab was administered by subcutaneous (SC) injection. At the Baseline Visit (Week 0), all participants received an initial dose of 80 mg adalimumab SC. Every other week (odd-numbered weeks) from Week 1 to Week 15, participants received 40 mg adalimumab SC.

This was a single group assignment study, that is, all participants received the same treatment; however, data were summarized for 3 groups (sub-studies) that were defined by psoriasis treatments participants received before entering this study: methotrexate, etanercept, or narrow-band, ultraviolet-B.

Efficacy was evaluated using the Physician's Global Assessment (PGA) of disease severity, and patient-reported outcomes: Patient's Global Assessment (PTGA) of disease severity, the Psoriasis-related Pruritus Assessment, the Dermatology Life Quality Index (DLQI), a visual analog scale (VAS) for plaque psoriasis and psoriatic arthritis pain, the Medical Outcomes Study (MOS) Sleep Scale, and the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI: SHP).

Serious and nonserious adverse events were summarized by sub-study of participants (suboptimal response to MTX, suboptimal response to NB-UVB, and suboptimal response to etanercept).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of chronic plaque psoriasis with disease duration of at least 6 months
  • Sub-optimal response to treatment with etanercept, methotrexate, or narrow-band UVB phototherapy

Exclusion Criteria:

  • Prior treatment with adalimumab
  • Multiple concomitant therapy restrictions and/or washouts (topicals, ultraviolet, other systemic psoriasis therapies)
  • Prior treatment with natalizumab
  • Concurrent active skin diseases/infections
  • Poorly controlled medical conditions
  • History of neurologic symptoms suggestive of central nervous system (CNS) demyelinating disease
  • History of certain cancers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00566722

  Hide Study Locations
Locations
United States, Alabama
Total Skin and Beauty Dermatology Centers
Birmingham, Alabama, United States, 35205
United States, Arkansas
Dermatology Research of Arkansas
Little Rock, Arkansas, United States, 72205
United States, California
Therapeutics Clinical Research
San Diego, California, United States, 92123
United States, Florida
Florida Academic Dermatology Centers
Miami, Florida, United States, 33136
United States, Georgia
Peachtree Dermatology Associates
Atlanta, Georgia, United States, 30327
United States, Indiana
Dawes Fretzin Clinical Research Group
Indianapolis, Indiana, United States, 46256
United States, Massachusetts
ORA Clinical Research and Development
Andover, Massachusetts, United States, 01810
United States, New York
Montifiore Medical Center
Bronx, New York, United States, 10467
Mount Sinai School of Medicine
New York, New York, United States, 10029
New York University School of Medicine
New York, New York, United States, 10016
United States, Pennsylvania
Paddington Testing Co.
Philadelphia, Pennsylvania, United States, 19103
United States, Rhode Island
Clinical Partners
Johnston, Rhode Island, United States, 02919
United States, South Carolina
Radiant Research
Greer, South Carolina, United States, 29651
United States, Texas
Dermatology Treatment & Research Center, PA Research
Dallas, Texas, United States, 75230
Baylor Research Institute
Dallas, Texas, United States, 75246
Center for Clinical Studies
Houston, Texas, United States, 77058
United States, Virginia
Virginia Clinical Research, Inc.
Norfolk, Virginia, United States, 23507
United States, Washington
Dermatology Associates
Seattle, Washington, United States, 98101
Canada, Alberta
Kirk Barber Research
Calgary, Alberta, Canada, T2S 3B3
Stratica Medical
Edmonton, Alberta, Canada, T5K 1X3
Canada, Nova Scotia
Eastern Canada Cutaneous Research Associates
Halifax, Nova Scotia, Canada, B3H 1Z4
Canada, Ontario
Dermatrials Research
Hamilton, Ontario, Canada, L8N 1V6
K.Papp Clinical Research Inc
Waterloo, Ontario, Canada, N2J 1C4
Canada, Quebec
Siena Medical Research
Montreal, Quebec, Canada
Centre de Rescherche Dermatologique Du Quebec Metropolitain
Quebec City, Quebec, Canada, G1V 4X7
Sponsors and Collaborators
Abbott
Investigators
Study Director: Martin M Okun, M.D., Ph.D. Abbott
  More Information

No publications provided by Abbott

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Marie Rosenfeld, CRM, Abbott
ClinicalTrials.gov Identifier: NCT00566722     History of Changes
Other Study ID Numbers: M10-238
Study First Received: December 1, 2007
Results First Received: April 28, 2010
Last Updated: April 8, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Adalimumab
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Antirheumatic Agents

ClinicalTrials.gov processed this record on September 16, 2014